<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005627</url>
  </required_header>
  <id_info>
    <org_study_id>DFCI-98238</org_study_id>
    <secondary_id>CDR0000067775</secondary_id>
    <secondary_id>RP-DFCI-98238</secondary_id>
    <secondary_id>NCI-G00-1779</secondary_id>
    <nct_id>NCT00005627</nct_id>
  </id_info>
  <brief_title>Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy</brief_title>
  <official_title>A Phase I Study of Estramustine, Taxotere and Carboplatin (ETP) in Patients With Horomone Refractory Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of estramustine, docetaxel, and carboplatin&#xD;
      in treating patients who have prostate cancer that has not responded to hormonal therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of weekly docetaxel when combined with carboplatin&#xD;
           and estramustine in patients with hormone refractory prostate cancer.&#xD;
&#xD;
        -  Determine the safety and efficacy of this regimen in this patient population.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of docetaxel.&#xD;
&#xD;
      Patients receive oral estramustine 3 times daily on days 1-5 and docetaxel IV over 1 hour on&#xD;
      day 2 of weeks 1-3. Patients also receive carboplatin IV over 1 hour on day 2 of week 1 only.&#xD;
      Treatment continues every 28 days for up to 6 courses in the absence of unacceptable toxicity&#xD;
      or disease progression.&#xD;
&#xD;
      Cohorts of 3-5 patients receive escalating doses of docetaxel until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 5 patients experience dose-limiting toxicity.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-30 patients will be accrued for this study within 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1999</start_date>
  <completion_date type="Actual">April 2003</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estramustine phosphate sodium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the prostate&#xD;
&#xD;
          -  Disease progression following androgen ablation therapy (hormonal or surgical) by&#xD;
             either:&#xD;
&#xD;
               -  Increase in the product of bidimensional diameters of 1 or more radiographically&#xD;
                  documented sites of measurable disease OR&#xD;
&#xD;
               -  Two consecutive increases in PSA documented over a previous reference value&#xD;
&#xD;
                    -  First increase in PSA should occur a minimum of 1 week from the reference&#xD;
                       value and be confirmed&#xD;
&#xD;
                    -  First PSA value is less than the previous value, then patient is eligible&#xD;
                       provided next PSA is greater than the second PSA&#xD;
&#xD;
          -  Testosterone levels documented in the castrate range (i.e., less than 30 ng/mL)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 to 85&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  CALGB 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  SGOT no greater than 2.5 times upper limit of normal (ULN) if alkaline phosphatase&#xD;
             normal OR&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 4 times ULN if SGOT normal OR&#xD;
&#xD;
          -  SGOT no greater than 1.5 times ULN and alkaline phosphatase no greater than 2.5 times&#xD;
             ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No myocardial infarction within past year&#xD;
&#xD;
          -  No significant change in anginal pattern within past 6 months&#xD;
&#xD;
          -  No New York Heart Association class II-IV heart disease&#xD;
&#xD;
          -  No deep venous thrombosis within past year&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No significant peripheral neuropathy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Prior chemotherapy allowed except taxanes or platinum derivatives&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior antiandrogens&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Oh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PW. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2005 Jan 1;11(1):284-9.</citation>
    <PMID>15671557</PMID>
  </results_reference>
  <verification_date>April 2003</verification_date>
  <study_first_submitted>May 2, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>recurrent prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Estramustine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

